Kiromic BioPharma Reports First Quarter 2021 Financial Results and Continued Corporate Progress
Upcoming Investigational New Drug Application Submissions
Facility Expansion in
SBA Loan Extinguishment
Research
“Kiromic BioPharma achieved important scientific and operational milestones during the year that we believe have us well positioned for preparing our staff and our facilities for the first in-human dosing in Q3 2021,” said Dr. Maurizio Chiriva-Internati, PhD, CEO and President of
Our approach and goal are to defeat cancer by developing immunotherapies by improving target discovery and validation. With better targets, we believe our therapies will be more effective than the current array of immunotherapies using older targets.
Corporate and Scientific Highlights
Events Occurring during the three months ended
-
Facility Expansion in
Houston, TX - OnMarch 22, 2021 , we executed a lease expansion within our premises inHouston, TX. The amended lease agreement will commence onAugust 1, 2021 under an operating lease agreement that is noncancelable from commencement untilMay 1, 2024 . The amended lease agreement adds approximately 15,385 square feet to the current facility. Total square feet will be approximately 38,223 square feet. -
Leon Office,Asia , Strategic Marketing Agreement – OnJanuary 28, 2021 , we executed a strategic alliance agreement withLeon Office,Asia (H.K.) (“Leon”) a company established under existing laws ofHong Kong .Leon will act as an independent business development advisor on the behalf of the Company.Leon will seek to introduce organizations and individuals that will create business development opportunities for the Company, to expand the Company’s reach to international markets with a focus on certain Asian markets and to increase brand recognition and exposure through developing liaisons, collaborations, branches and subsidiaries. They will also use commercially reasonable efforts to research the Asian market, with a primary, but not exclusive, focus on determining the most suitable structures for the development of medical partnerships or joint ventures with scientific partners in the Asian market with a mission to test products to be created by the joint venture resulting from such partnership and to develop validation programs for any products produced by such joint venture, including programs for clinical trials and human testing and, ultimately, for product certification. The cost of the agreement is$360,000 annually, payable in four quarterly installments. -
SBA Loan Extinguishment - On
February 16, 2021 theSmall Business Administration (“SBA”) granted forgiveness of our SBA loan and all applicable interest. On the date of forgiveness, the principal and accrued interest totaled$105,800 . The forgiveness was classified as a gain on loan extinguishment in the consolidated statement of operations.
Events occurring after
-
Research
Grant Agreement withUniversity of Texas MD Anderson Cancer Center – OnApril 8, 2021 , we entered into a letter of intent (the “Letter of Intent”) with theUniversity of Texas MD Anderson Cancer Center (“MD Anderson”) pursuant to which MD Anderson shall receive a research grant from us entitled, “Validation of biomarker isomeso for pancreatic cancer,” which is aimed at discovering new cancer-specific antigen targets (the “Grant”). The total costs to us to be paid in connection with the Grant shall be$300,000 . Pursuant to the Letter of Intent, the Grant shall commence onApril 1, 2021 and end onMarch 31, 2022 . -
Upcoming Investigational New Drug Application Submissions – We are planning to submit two investigational new drug (“IND”) applications to the
United States Food and Drug Administration by the end ofMay 2021 . These INDs will be for our ALEXIS-PRO-1 and ALEXIS-ISO-1 product candidates. ALEXIS-PRO-1 is our allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. ALEXIS-ISO-1 is our allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin (the isoform of Mesothelin).
Q1 2021 Financial Highlights
Cash Position: Cash and cash equivalents were
R&D Expenses: Our research and development expenses increased by
G&A Expenses: Our general and administrative expenses increased by
Net Loss: Our net loss increased to
About
Forward-looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the
- our goals and strategies;
- our future business development, financial condition and results of operations;
- expected changes in our revenue, costs or expenditures;
- growth of and competition trends in our industry;
- our expectations regarding demand for, and market acceptance of, our products;
- our expectations regarding our relationships with investors, institutional funding partners and other parties we collaborate with;
- fluctuations in general economic and business conditions in the markets in which we operate; including those fluctuations caused by COVID-19; and
- relevant government policies and regulations relating to our industry.
In some cases, you can identify forward-looking statements by terms such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the heading “Risk Factors” included in our Annual Report on Form 10-K (file no. 001-39169), filed with the
The forward-looking statements made in this report relate only to events or information as of the date on which the statements are made in this report. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.
Condensed Consolidated Balance Sheets |
||||||||
|
||||||||
|
|
|
|
|
||||
|
|
2021 |
|
2020 |
||||
Assets |
|
|
|
|
||||
Current Assets: |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
7,335,300 |
|
|
$ |
10,150,500 |
|
Prepaid expenses and other current assets |
|
|
513,500 |
|
|
|
588,800 |
|
Total current assets |
|
|
7,848,800 |
|
|
|
10,739,300 |
|
Property and equipment, net |
|
|
2,279,500 |
|
|
|
2,066,000 |
|
Other assets |
|
|
24,400 |
|
|
|
24,400 |
|
Total Assets |
|
$ |
10,152,700 |
|
|
$ |
12,829,700 |
|
|
|
|
|
|
||||
Liabilities and Stockholders’ Equity: |
|
|
|
|
||||
Current Liabilities: |
|
|
|
|
||||
Accounts payable |
|
$ |
1,203,200 |
|
|
$ |
665,200 |
|
Accrued expenses and other current liabilities |
|
|
268,900 |
|
|
|
334,200 |
|
Interest payable |
|
|
— |
|
|
|
200 |
|
Loan payable |
|
|
— |
|
|
|
105,600 |
|
Note payable |
|
|
227,800 |
|
|
|
362,400 |
|
Total current liabilities |
|
|
1,699,900 |
|
|
|
1,467,600 |
|
|
|
|
|
|
||||
Total Liabilities |
|
|
1,699,900 |
|
|
|
1,467,600 |
|
|
|
|
|
|
||||
Commitments and contingencies (Note 8) |
|
|
|
|
||||
Stockholders’ Equity: |
|
|
|
|
||||
Common stock, |
|
|
1,200 |
|
|
|
1,200 |
|
Additional paid-in capital |
|
|
53,933,900 |
|
|
|
52,988,700 |
|
Accumulated deficit |
|
|
(45,482,300 |
) |
|
|
(41,627,800 |
) |
Total Stockholders’ Equity |
|
|
8,452,800 |
|
|
|
11,362,100 |
|
|
|
|
|
|
||||
Total Liabilities and Stockholders’ Equity |
|
$ |
10,152,700 |
|
|
$ |
12,829,700 |
|
Condensed Consolidated Statements of Operations |
||||||||
|
|
|
|
|||||
|
|
Three Months Ended |
||||||
|
|
|
||||||
|
|
2021 |
|
2020 |
||||
Operating expenses: |
|
|
|
|
||||
Research and development |
|
$ |
1,885,600 |
|
|
$ |
1,028,100 |
|
General and administrative |
|
|
2,071,000 |
|
|
|
824,600 |
|
Total operating expenses |
|
|
3,956,600 |
|
|
|
1,852,700 |
|
Loss from operations |
|
|
(3,956,600 |
) |
|
|
(1,852,700 |
) |
Other income (expense) |
|
|
|
|
||||
Gain on loan extinguishment |
|
|
105,800 |
|
|
|
— |
|
Interest expense |
|
|
(3,700 |
) |
|
|
— |
|
Total other expense |
|
|
102,100 |
|
|
|
— |
|
Net loss |
|
$ |
(3,854,500 |
) |
|
$ |
(1,852,700 |
) |
Net loss per share, basic and diluted |
|
$ |
(0.53 |
) |
|
$ |
(0.78 |
) |
Weighted average common shares outstanding, basic and diluted |
|
|
7,332,999 |
|
|
|
2,863,812 |
|
Condensed Consolidated Statements of Cash Flows |
||||||||
|
|
|
|
|
||||
|
|
Three Months Ended |
||||||
|
|
|
||||||
|
|
2021 |
|
2020 |
||||
Cash flows from operating activities: |
|
|
|
|
||||
Net loss |
|
$ |
(3,854,500 |
) |
|
$ |
(1,852,700 |
) |
Adjustments to reconcile net loss to net cash used for operating activities: |
|
|
|
|
||||
Depreciation |
|
|
95,600 |
|
|
|
33,800 |
|
Stock compensation expense |
|
|
945,200 |
|
|
|
456,000 |
|
Gain on loan extinguishment |
|
|
(105,800 |
) |
|
|
— |
|
Changes in operating assets and liabilities: |
|
|
|
|
||||
Prepaid expenses and other current assets |
|
|
75,400 |
|
|
|
(99,700 |
) |
Accounts payable |
|
|
273,600 |
|
|
|
(35,200 |
) |
Accrued expenses and other current liabilities |
|
|
(65,400 |
) |
|
|
17,500 |
|
Net cash used for operating activities |
|
|
(2,635,900 |
) |
|
|
(1,480,300 |
) |
Cash flows from investing activities: |
|
|
|
|
||||
Purchases of property and equipment |
|
|
(44,700 |
) |
|
|
(406,300 |
) |
Net cash used for investing activities |
|
|
(44,700 |
) |
|
|
(406,300 |
) |
Cash flows from financing activities: |
|
|
|
|
||||
Repayments of note payable |
|
|
(134,600 |
) |
|
|
— |
|
Proceeds from Series B Preferred Stock issuance |
|
|
— |
|
|
|
3,000,000 |
|
Net cash (used in) provided by financing activities |
|
|
(134,600 |
) |
|
|
3,000,000 |
|
Net change in cash and cash equivalents |
|
|
(2,815,200 |
) |
|
|
1,113,400 |
|
Cash and cash equivalents: |
|
|
|
|
||||
Beginning of year |
|
|
10,150,500 |
|
|
|
1,929,100 |
|
End of period |
|
$ |
7,335,300 |
|
|
$ |
3,042,500 |
|
|
|
|
|
|
||||
Supplemental disclosures of non-cash investing and financing activities: |
|
|
|
|
||||
Accruals for property and equipment |
|
$ |
264,400 |
|
|
$ |
230,700 |
|
Cash paid for interest on note payable |
|
$ |
3,700 |
|
|
$ |
— |
|
Warrants underlying Series B Preferred Stock issuance |
|
$ |
— |
|
|
$ |
2,668,300 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20210514005463/en/
Chief Financial Officer
628-777-3167
Bus.dev@kiromic.com
Source: